Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine vs Dexmedetomidine for Emergence Agitation in Children
NCT06830564Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- May 2024
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nalbuphine in emergence delirium (ED) (2 arms), sponsored by Ain Shams University. Primary endpoint: Incidence of emergence agitation after sevoflurane anaesthesia at 30 months. Started May 2024; status: completed.
02
Drugs
nalbuphine
03
Conditions
emergence delirium (ED)
Beyond the preview
Go deeper on NCT06830564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830564.